- Home
- LEGH vs FDMT Comparison
LEGH vs FDMT Comparison
Compare LEGH & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LEGH | FDMT |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 495.0M | 455.4M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LEGH | FDMT |
|---|---|---|
| Price | $19.63 | $7.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $25.00 | ★ $30.33 |
| AVG Volume (30 Days) | 116.9K | ★ 1.2M |
| Earning Date | 11-07-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.95 | N/A |
| Revenue | ★ $180,497,000.00 | $120,000.00 |
| Revenue This Year | N/A | $21,181.08 |
| Revenue Next Year | $6.07 | $162.43 |
| P/E Ratio | $10.01 | ★ N/A |
| Revenue Growth | 10.25 | ★ 605.88 |
| 52 Week Low | $18.84 | $2.24 |
| 52 Week High | $29.45 | $12.34 |
Technical Indicators
Market Signals| Indicator | LEGH | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 39.81 | 31.59 |
| Support Level | $19.56 | $7.67 |
| Resistance Level | $19.95 | $11.81 |
| Average True Range (ATR) | 0.52 | 0.73 |
| MACD | 0.01 | -0.27 |
| Stochastic Oscillator | 0.00 | 1.60 |
Price Performance
Historical ComparisonAbout LEGH Legacy Housing Corporation (TX)
Legacy Housing Corp builds, sell, and finance manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores and also sold directly to manufactured home communities. The company also provides financing options to its customers to facilitate the sale of homes.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.